Business
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed, Refractory Solid Tumors
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in
About this update from Instil Bio, Inc.
[{"type":"text","content":"DALLAS - Instil Bio, Inc. ('Instil') (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (''2510') by the U.S. Food and Drug Administration.\nInstil expects to initiate a phase 1 trial of '2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of '2510 in patients with solid tumors. Additionally, Instil continues to anticipate that initial safety and efficacy results from the ongoing phase 2 study of '2510 in combination with chemotherapy in first-line NSCLC in China will be shared in the second half of 2025 by ImmuneOnco.\n'We are pleased to announce the clearance of the '2510 IND by the FDA,' said Jamie Freedman, M.D., Ph.D., Chief Medical Officer of Instil. 'Evaluating '2510 in a global population will be a critical milestone in the clinical development of '2510.'\nAbout Instil BioInstil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors.\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words (and variations of words) such as 'anticipates,' 'believes,' 'could,' expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'will,' 'target,' and similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding Instil's expectations with respect to the therapeutic potential of AXN-2510, the clinical development of AXN-2510, patient enrollment and clinical trials and the timing, scope and design thereof, and the availability and timing of data from clinical trials. Forward-looking statements are based on Instil management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and...